Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

ties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with GAAP and related standards. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the Company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors set forth in the Company's Report on Form 10-Q, for the quarter ended September 30, 2010, and in its other filings with the SEC. Further, uncertainties or other circumstances, or matters outside of the Company's control between the date of this release and the date that its Form 10-K for the year ended December 31, 2010, is filed with the SEC could potentially result in adjustments to reported results. The Company undertakes no obligation to update statements herein for revisions or changes after the date of this release.

Mylan Inc. and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited; in thousands, except per share amounts)Three Months Ended
December 31,Year Ended
December 31,2010200920102009Revenues:Net revenues

$
,424,618$
,335,526$
5,404,266$
5,015,394Other revenues

9,88116,29146,25677,391Total revenues

1,434,4991,351,8175,450,5225,092,785Cost of sales

855,307835,8263,233,1253,018,313Gross profit

579,192515,9912,217,3972,074,472Operating expenses:Research and development

82,07072,593282,146275,258Selling, general and administrative

290,189269,1911,086,6091,050,145Litigation settlements, net

112,759114,187127,058225,717Total operating expenses

485,018455,9711,495,8131,551,120Earnings from operations

94,17460,020721,584523,352Interest expense

91,47778,287331,462318,496Other (expense) income, net

(4,740)(7,622)(34,178)2
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... tru Shrimp™ Systems announced today that it has ... the exclusive worldwide rights to commercialize Tidal Basin™ technology, ... agreement for the patented technology, developed by world-renowned shrimp ... China, Taiwan, France, Germany, Italy, Spain, the Netherlands and ... from all over the world for our Tidal Basin™ ...
(Date:4/24/2015)... April 24, 2015 Top student social ... San Diego area universities, including UCSD and SDSU, will ... from prominent local, national and nonprofit companies for an ... 5th Annual Social Innovation Challenge 2015 . , ... social venture ideas addressing a diverse range of issues ...
(Date:4/24/2015)... DIEGO , April 24, 2015  Pfenex Inc. ... the development of biosimilar therapeutics including high value and ... its follow-on public offering of 6,000,000 shares of its ... $15.50 per share. Of the shares being offered, 2,610,000 ... shares are being offered by existing stockholders. Pfenex will ...
Breaking Biology Technology:SynGen Inc. Expands Its Management Team 2tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... LA JOLLA, Calif., March 18 TorreyPines Therapeutics,Inc. ... initiated a Phase II study of,NGX267, a muscarinic ... to Sjogren,s syndrome., The company is conducting ... square design to evaluate,the safety, tolerability and efficacy ...
... NEOG ) announces the following Webcast:, What: Neogen ... EDT, Where: http://www.videonewswire.com/event.asp?id=46587 , How: ... the address above., ... are unable to participate during the live webcast, the call will,be archived ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,344,711 entitled "Use of Adenoviruses Mutated in the,VA ... of treating,cancer using adenoviruses that are modified to ... Ras pathway., "This patent expands our adenovirus ...
Cached Biology Technology:TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... LEDs may help reduce skin ... in Germany are describing a potential alternative to Botox ... scheduled for the November 5 issue of ACS, ... that high intensity visible light from light emitting diodes ...
... cleavage product, amyloid-b (Ab), builds up into fibrous plaques ... one specialized membrane microdomain to another to be cleaved, ... definitive evidence that Ab plaques are the direct cause ... support this. And working on this hypothesis, scientists are ...
... one step closer to finding a vaccine that better ... at Saint Louis University appears likely to offer significantly ... one in current use. "Not only was it ... better immune response, which suggests it will be more ...
Cached Biology News:American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8Research identifies type of vaccine that holds promise in protecting against TB 2
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: polystyrene ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: